# Substance Use Disorder (SUD)-Associated Infections' Treatment With Dalbavancin ENabling OUtpatient Transition

> **NCT04847921** · PHASE2,PHASE3 · TERMINATED · sponsor: **University of Colorado, Denver** · enrollment: 11 (actual)

## Conditions studied

- Gram-Positive Bacterial Infections
- Gram-Positive Bacteraemia
- Substance Use Disorders
- Intravenous Substance Abuse

## Interventions

- **DRUG:** Dalbavancin

## Key facts

- **NCT ID:** NCT04847921
- **Lead sponsor:** University of Colorado, Denver
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-04-30
- **Primary completion:** 2023-10-05
- **Final completion:** 2023-10-05
- **Target enrollment:** 11 (ACTUAL)
- **Why stopped:** Delays in recruitment due to COVID-19 and higher than acceptable loss to followup.
- **Last updated:** 2023-10-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04847921

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04847921, "Substance Use Disorder (SUD)-Associated Infections' Treatment With Dalbavancin ENabling OUtpatient Transition". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04847921. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*